Targeted drug tested for Tough-to-Treat leukemia subtype

This early-stage study is testing if the drug Talazoparib can help control two types of blood cancer (AML and MDS) in patients whose cancers have a specific genetic change called a cohesin mutation. The drug works by blocking a protein that helps cancer cells repair themselves, which lab tests suggest might be especially effective against cancers with this mutation. The study aims to see if the drug safely reduces the number of cancer cells in a small group of adult patients who have few other treatment options.